These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25135005)

  • 21. Private and public willingness to pay for safety: A validity test.
    Andersson H; Levivier E; Lindberg G
    Accid Anal Prev; 2019 Feb; 123():170-175. PubMed ID: 30517899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The willingness to pay for in vitro fertilization: a pilot study using contingent valuation.
    Neumann PJ; Johannesson M
    Med Care; 1994 Jul; 32(7):686-99. PubMed ID: 8028404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.
    Mavrodi A; Aletras V
    Value Health Reg Issues; 2020 Sep; 22():36-43. PubMed ID: 32731168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability and Validity of the Contingent Valuation Method for Estimating Willingness to Pay: A Case of In Vitro Fertilisation.
    Settumba SN; Shanahan M; Botha W; Ramli MZ; Chambers GM
    Appl Health Econ Health Policy; 2019 Feb; 17(1):103-110. PubMed ID: 30315488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan.
    Tang CH; Liu JT; Chang CW; Chang WY
    Health Policy; 2007 Jul; 82(2):251-62. PubMed ID: 17084480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VOLY: The Monetary Value of a Life-Year at the End of Patients' Lives.
    Ribarić E; Velić I; Bobinac A
    Appl Health Econ Health Policy; 2024 Jan; 22(1):97-106. PubMed ID: 37792263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The contingent valuation method in health care.
    Klose T
    Health Policy; 1999 May; 47(2):97-123. PubMed ID: 10538292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement.
    Jacobs RJ; Moleski RJ; Meyerhoff AS
    Pharmacoeconomics; 2002; 20(11):739-47. PubMed ID: 12201793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Willingness to pay for antihypertensive therapy--results of a Swedish pilot study.
    Johannesson M; Jönsson B; Borgquist L
    J Health Econ; 1991; 10(4):461-73. PubMed ID: 10117014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring a new method for deriving the monetary value of a QALY.
    Tilling C; Krol M; Attema AE; Tsuchiya A; Brazier J; van Exel J; Brouwer W
    Eur J Health Econ; 2016 Sep; 17(7):801-9. PubMed ID: 26289341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?
    Ungar WJ
    Pharmacoeconomics; 2011 Aug; 29(8):641-52. PubMed ID: 21604821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the value of a new pharmaceutical. A feasibility study of contingent valuation in managed care.
    O'Brien BJ; Goeree R; Gafni A; Torrance GW; Pauly MV; Erder H; Rusthoven J; Weeks J; Cahill M; LaMont B
    Med Care; 1998 Mar; 36(3):370-84. PubMed ID: 9520961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appraising the use of contingent valuation.
    Morrison GC; Gyldmark M
    Health Econ; 1992 Dec; 1(4):233-43. PubMed ID: 1341939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sources of traffic and visitors' preferences regarding online public reports of quality: web analytics and online survey results.
    Bardach NS; Hibbard JH; Greaves F; Dudley RA
    J Med Internet Res; 2015 May; 17(5):e102. PubMed ID: 25934100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of consumer-patient preferences using a hybrid contingent valuation method.
    O'Conor RM; Blomquist GC
    J Health Econ; 1997 Dec; 16(6):667-83. PubMed ID: 10176778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
    Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost-benefit analysis using contingent valuation techniques: a feasibility study in spinal surgery.
    Haefeli M; Elfering A; McIntosh E; Gray A; Sukthankar A; Boos N
    Value Health; 2008; 11(4):575-88. PubMed ID: 18179657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discounting in decision making: the consistency argument revisited empirically.
    Brouwer WB; van Exel NJ
    Health Policy; 2004 Feb; 67(2):187-94. PubMed ID: 14720636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Community and patient values for preventing herpes zoster.
    Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
    Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Willingness to pay for a quality-adjusted life-year: the individual perspective.
    Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.